|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC2A11 |
Gene summary for SLC2A11 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC2A11 | Gene ID | 66035 |
| Gene name | solute carrier family 2 member 11 | |
| Gene Alias | GLUT10 | |
| Cytomap | 22q11.23 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q6PJ99 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 66035 | SLC2A11 | HCC1_Meng | Human | Liver | HCC | 4.66e-24 | 5.78e-02 | 0.0246 |
| 66035 | SLC2A11 | S014 | Human | Liver | HCC | 6.85e-15 | 5.92e-01 | 0.2254 |
| 66035 | SLC2A11 | S015 | Human | Liver | HCC | 2.17e-15 | 6.64e-01 | 0.2375 |
| 66035 | SLC2A11 | S016 | Human | Liver | HCC | 6.13e-20 | 6.95e-01 | 0.2243 |
| 66035 | SLC2A11 | S028 | Human | Liver | HCC | 3.14e-07 | 3.85e-01 | 0.2503 |
| 66035 | SLC2A11 | S029 | Human | Liver | HCC | 8.66e-06 | 3.55e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0008643 | Liver | HCC | carbohydrate transport | 80/7958 | 152/18723 | 7.34e-03 | 2.92e-02 | 80 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC2A11 | SNV | Missense_Mutation | c.1013G>T | p.Gly338Val | p.G338V | protein_coding | tolerated(0.59) | benign(0) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SLC2A11 | SNV | Missense_Mutation | c.1306C>A | p.Arg436Ser | p.R436S | protein_coding | deleterious(0.04) | benign(0.007) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| SLC2A11 | SNV | Missense_Mutation | c.1201G>A | p.Ala401Thr | p.A401T | protein_coding | tolerated(0.25) | benign(0.175) | TCGA-BH-A18Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| SLC2A11 | SNV | Missense_Mutation | novel | c.106N>C | p.Gly36Arg | p.G36R | protein_coding | deleterious(0.01) | probably_damaging(0.991) | TCGA-HN-A2NL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
| SLC2A11 | insertion | In_Frame_Ins | novel | c.96_97insGTC | p.Thr32_Phe33insVal | p.T32_F33insV | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | |||
| SLC2A11 | insertion | In_Frame_Ins | novel | c.98_99insCCCCAAACACAGCAGACGTGC | p.Phe33_Gln34insProLysHisSerArgArgAla | p.F33_Q34insPKHSRRA | protein_coding | TCGA-A2-A0D1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | |||
| SLC2A11 | SNV | Missense_Mutation | rs540314158 | c.992C>T | p.Thr331Met | p.T331M | protein_coding | tolerated(0.12) | benign(0.015) | TCGA-A6-A566-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | PD | |
| SLC2A11 | SNV | Missense_Mutation | novel | c.1054N>C | p.Thr352Pro | p.T352P | protein_coding | deleterious(0.01) | benign(0.207) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| SLC2A11 | SNV | Missense_Mutation | rs768582330 | c.368N>A | p.Arg123His | p.R123H | protein_coding | tolerated(0.18) | benign(0.028) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| SLC2A11 | SNV | Missense_Mutation | novel | c.967N>A | p.Gly323Arg | p.G323R | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |